Acorda Therapeutics INC Stock: price and directors' dealings · United States · SEC (Form 4)

About Acorda Therapeutics INC

Acorda Therapeutics Inc. is a U.S.-based biopharmaceutical company that historically focused on neurological disorders and functional recovery. The company was listed on the NASDAQ market in the United States, and its operations were built around specialty drugs aimed at improving mobility and quality of life for patients with chronic nervous-system conditions. Acorda was founded in the early 1990s and was long headquartered in Pearl River, New York. Its corporate profile changed dramatically in 2024, when the company entered Chapter 11 bankruptcy protection and subsequently transferred substantially all of its operating assets. From an industry perspective, Acorda became known for developing and commercializing therapies in multiple sclerosis and Parkinson’s disease. Its best-known products were AMPYRA (dalfampridine), indicated in the U.S. to improve walking in certain patients with multiple sclerosis, and INBRIJA (levodopa inhalation powder), used for intermittent treatment of OFF episodes in patients with Parkinson’s disease treated with carbidopa/levodopa. The company also owned ARCUS, an inhalation-delivery technology platform that added strategic value beyond the marketed brands themselves. In addition, Acorda had international exposure through FAMPYRA, the ex-U.S. branded version of fampridine used in multiple sclerosis-related walking impairment. Before the restructuring, Acorda occupied a niche position in specialty neurology. It was not a broad diversified pharmaceutical player, but rather a focused commercial-stage biotech with a concentrated portfolio and a relatively small number of key assets. That made the business highly dependent on product performance, patent and lifecycle management, payer access, and regulatory execution. For investors, this meant the equity case was driven by asset-specific economics rather than scale. Recent developments are central to any current assessment. In 2024, Acorda entered Chapter 11 in the United States and agreed to sell substantially all of its assets to Merz Therapeutics, including INBRIJA, AMPYRA, and FAMPYRA. Company disclosures stated that Acorda exited Chapter 11 on August 21, 2024, and that remaining assets were transferred to the Acorda Therapeutics Liquidation Trust. In practical terms, Acorda’s former operating business was wound down, while the entity continued to appear in SEC filings, including insider Form 4 transactions. For international investors analyzing U.S. listed healthcare names, Acorda should now be viewed primarily as a restructuring/liquidation case rather than a going-concern growth pharmaceutical company.